Edoxaban for treatment of venous thromboembolism in patients with cancer: Rationale and design of the hokusai VTE-cancer study

Published on Aug 13, 2015in Thrombosis and Haemostasis4.733
· DOI :10.1160/TH15-06-0452
Nick van Es17
Estimated H-index: 17
(UvA: University of Amsterdam),
Marcello Di Nisio30
Estimated H-index: 30
+ 20 AuthorsGary E. Raskob73
Estimated H-index: 73
(OU: University of Oklahoma)
Direct oral anticoagulants may be effective and safe for treatment of venous thromboembolism (VTE) in cancer patients, but they have not been compared with low-molecular-weight heparin (LMWH), the current recommended treatment for these patients. The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer. We present the rationale and some design features of the study. One such feature is the composite primary outcome of recurrent VTE and major bleeding during a 12-month study period. These two complications occur frequently in cancer patients receiving anticoagulant treatment and have a significant impact. The evaluation beyond six months will fill the current gap in the evidence base for the long-term treatment of these patients. Based on the observation that the risk of recurrent VTE in patients with active cancer is similar to that in those with a history of cancer, the Hokusai VTE-cancer study will enrol patients if whose cancer was diagnosed within the past two years. In addition, patients with incidental VTE are eligible because their risk of recurrent VTE is similar to that in patients with symptomatic disease. The unique design features of the Hokusai VTE-cancer study should lead to enrolment of a broad spectrum of cancer patients with VTE who could benefit from oral anticoagulant treatment.
  • References (30)
  • Citations (59)
📖 Papers frequently viewed together
1,611 Citations
15 Authors (Clive Kearon, ..., Lisa K. Moores)
1,555 Citations
930 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Catch Investigators (UBC: University of British Columbia)H-Index: 1
Importance Low-molecular-weight heparin is recommended over warfarin for the treatment of acute venous thromboembolism (VTE) in patients with active cancer largely based on results of a single, large trial. Objective To study the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic VTE in patients with active cancer. Design, Settings, and Participants A randomized, open-label study with blinded central adjudication of study outcomes enrolled patients in 164 centers i...
237 CitationsSource
#1Charles W. Francis (URMC: University of Rochester Medical Center)H-Index: 69
#2Craig M. Kessler (Georgetown University)H-Index: 33
Last. Ajay K. Kakkar (QMUL: Queen Mary University of London)H-Index: 61
view all 12 authors...
SummaryBackground Treatment of venous thromboembolism (VTE) in patients with cancer has a high rate of recurrence and bleeding complications. Guidelines recommend low-molecular-weight heparin (LMWH) for at least 3–6 months and possibly indefinitely for patients with active malignancy. There are, however, few data supporting treatment with LMWH beyond 6 months. The primary aim of the DALTECAN study (NCT00942968) was to determine the safety of dalteparin between 6 and 12 months in cancer-associate...
87 CitationsSource
#1Marcello Di NisioH-Index: 30
#2Agnes Y.Y. Lee (VCH: Vancouver Coastal Health)H-Index: 42
Last. Alok A. Khorana (Cleveland Clinic)H-Index: 47
view all 5 authors...
Modern computer tomography (CT) with its higher sensitivity and resolution has increased the detection of incidental venous thromboembolism (VTE) in the venous and pulmonary vasculature during routine imaging for cancer staging and response assessment [1]. As a result, up to half of all VTEs diagnosed in oncology centers are incidental [1-5]. Although widely accepted, the diagnosis of incidental VTE is made without using the standard imaging studies required for confirming the presence of sympto...
42 CitationsSource
Venous thromboembolism (VTE) is a common occurrence in patients with malignant disease. Standard treatment for acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) is usually initial subcutaneous weight-adjusted low molecular weight heparin (LMWH), which is continued for approximately 6 months. The treatment of acute DVT and/or PE is to prevent recurrent thromboembolism. In one prospective study, the cumulative incidence of recurrent VTE at 12 months was approximately 20% in patients ...
3 CitationsSource
#1Elie A. Akl (AUB: American University of Beirut)H-Index: 72
#2Lara A. Kahale (AUB: American University of Beirut)H-Index: 14
Last. Holger J. Schünemann (McMaster University)H-Index: 109
view all 9 authors...
Background Cancer increases the risk of thromboembolic events, especially in people receiving anticoagulation treatments. Objectives To compare the efficacy and safety of low molecular weight heparins (LMWHs), direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) for the long-term treatment of venous thromboembolism (VTE) in people with cancer. Search methods We conducted a literature search including a major electronic search of the Cochrane Central Register of Controlled Trials (...
190 CitationsSource
#1Nick van EsH-Index: 17
#2Suzanne M. BlekerH-Index: 9
Last. Marcello Di NisioH-Index: 30
view all 3 authors...
ABSTRACT Clinically unsuspected pulmonary embolism (UPE) is frequently diagnosed in cancer patients undergoing routine computed tomography scans for staging purposes or treatment response evaluation. The reported incidence of UPE ranges from 1% to 5% which probably represents an underestimation. A significant proportion of cancer patients with UPE actually do have pulmonary embolism (PE) related symptoms. However, these can erroneously be attributed to the cancer itself or to cancer therapy lead...
31 CitationsSource
#1Harry R. BüllerH-Index: 92
#2Pantep Angchaisuksiri (MU: Mahidol University)H-Index: 23
Last. Michele Mercuri (Daiichi Sankyo)H-Index: 26
view all 9 authors...
![Graphic][1] Low-molecular-weight heparin (LMWH) is recommended for long-term anticoagulant therapy in cancer patients with venous thromboembolism (VTE). These patients have been mostly excluded from clinical trials comparing new oral anticoagulants with vitamin-K antagonists. Hokusai-VTE was a global randomized, double-blind, non-inferiority trial (margin 1.5) that compared edoxaban, an oral factor Xa inhibitor, with warfarin for long-term therapy in 8,292 patients with acute symptomatic proxi...
19 CitationsSource
#1Harry R. BüllerH-Index: 92
#2Hervé DecoususH-Index: 38
Last. Phil WellsH-Index: 5
view all 11 authors...
Methods In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolis...
930 CitationsSource
#1Jasmijn F. Timp (LUMC: Leiden University Medical Center)H-Index: 4
#2Sigrid K. Brækkan (University of Tromsø)H-Index: 21
Last. Suzanne C. Cannegieter (LUMC: Leiden University Medical Center)H-Index: 41
view all 4 authors...
Cancer-associated venous thrombosis is a common condition, although the reported incidence varies widely between studies depending on patient population, start and duration of follow-up, and the method of detecting and reporting thrombotic events. Furthermore, as cancer is a heterogeneous disease, the risk of venous thrombosis depends on cancer types and stages, treatment measures, and patient-related factors. In general, cancer patients with venous thrombosis do not fare well and have an increa...
321 CitationsSource
#1Giancarlo A (University of Perugia)H-Index: 75
#2Harry R. BüllerH-Index: 92
Last. Jeffrey I. WeitzH-Index: 90
view all 11 authors...
METHODS In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relev...
1,049 CitationsSource
Cited By59
#1Frits I. Mulder (UvA: University of Amsterdam)H-Index: 2
#2Marcello Di NisioH-Index: 30
Last. Nick van Es (UvA: University of Amsterdam)H-Index: 17
view all 17 authors...
Introduction In cancer patients, current guidance suggests similar treatment for incidental and symptomatic venous thromboembolism (VTE), mainly based on retrospective data. We aimed to evaluate anticoagulant therapy in cancer patients with incidental and symptomatic VTE. Methods The Hokusai VTE Cancer study was a randomised controlled trial comparing edoxaban with dalteparin for cancer-associated VTE. The primary outcome was the composite of first recurrent VTE or major bleeding. Secondary outc...
1 CitationsSource
#1Jeroen T. Buijs (LUMC: Leiden University Medical Center)H-Index: 22
#2El Houari Laghmani (LUMC: Leiden University Medical Center)H-Index: 11
Last. Henri H. Versteeg (LUMC: Leiden University Medical Center)H-Index: 27
view all 11 authors...
2 CitationsSource
#1Megan K Phelps (OSU: Ohio State University)H-Index: 1
#2Tracy E. Wiczer (OSU: Ohio State University)H-Index: 4
Last. Tzu-Fei Wang (OSU: Ohio State University)H-Index: 6
view all 7 authors...
IntroductionLow-molecular-weight heparins are the standard treatment for cancer-associated thrombosis. Recently, direct oral anticoagulants are a new option for thrombosis treatment; however, data supporting the use of direct oral anticoagulants for cancer-associated thrombosis are limited.ObjectivesThe primary objective of this study was to determine the rate of recurrent cancer-associated thrombosis and major bleeding within 6 months of starting either low-molecular-weight heparin or direct or...
1 CitationsSource
#1Andrea Cervi (McMaster University)H-Index: 1
#2James D. Douketis (McMaster University)H-Index: 71
Recent years have witnessed an onslaught of large, multicenter, randomized controlled trials evaluating the prevention and management of thrombotic vascular diseases. While these trials have applied rigorous methodology to pragmatic and clinically relevant questions, several important gaps in knowledge remain. In this review, we critically appraise landmark studies in thrombosis published between 2016 and 2017 that address several ongoing areas of clinical uncertainty. Specifically, we review th...
#1Giancarlo A (University of Perugia)H-Index: 75
#2Cecilia Becattini (University of Perugia)H-Index: 36
Last. Giorgio VescovoH-Index: 31
view all 17 authors...
International and national guidelines recommend low-molecular-weight heparin for the treatment of venous thromboembolism (VTE) in patients with cancer. The aim of the Caravaggio study is to assess whether oral apixaban is non-inferior to subcutaneous dalteparin for the treatment of acute proximal deep vein thrombosis and/or pulmonary embolism in patients with cancer. The study is an investigator-initiated, multi-national, prospective, randomized, open-label with blind end-point evaluation (PROBE...
16 CitationsSource
#1Noémie Kraaijpoel (UvA: University of Amsterdam)H-Index: 6
#2Marcello Di NisioH-Index: 30
Last. Gary E. Raskob (University of Oklahoma Health Sciences Center)H-Index: 73
view all 22 authors...
In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients with cancer-associated VTE. The absolute rate of recurrent VTE was 3.4% lower with edoxaban, whereas the absolute rate of major bleeding was 2.9% higher. The present analysis focuses on the sites, clinical presentation, course and outcome of bleeding events, and the associated tumour types. Major bleeds and their severit...
23 CitationsSource
#1Marissa D. Rybstein (NewYork–Presbyterian Hospital)H-Index: 1
#2Maria T. DeSancho (NewYork–Presbyterian Hospital)H-Index: 10
Inherited and acquired thrombophilias and hypercoagulable states, such as active cancer, estrogen-induced, autoimmune disorders, major surgery, hospitalization, and trauma, are well-known risk factors for venous thromboembolism (VTE). The effect of these on recurrent VTE is different for each specific risk factor. The major risk factors affecting VTE recurrence include the presence of active cancer and an unprovoked first VTE. In addition, the use of combined female hormones in a woman with a pr...
1 CitationsSource
#1Renato D. Lopes (Duke University)H-Index: 56
#2Patrícia O. Guimarães (Duke University)H-Index: 5
Last. David A. Garcia (UW: University of Washington)H-Index: 35
view all 8 authors...
To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Tenth International Symposium of Thrombosis and Anticoagulation was held in Salvador, Bahia, Brazil, on September 22 and 23, 2017. This scientific program was developed by clinicians for clinicians and was promoted by two major clinical research institutes—the Brazilian Clinical Research Institute and the Duke Clinical Research Institute of the Duke University School of Medicine. Comprising acade...
Abstract. In patients with solid tumours or haematological malignancies, venous thromboembolism (VTE) is a leading cause of death and significantly contributes to morbidity and healthcare resource utilization. Current practice guidelines recommend long-term anticoagulation with low-molecular-weight heparin (LMWH) as the treatment of choice for cancer-associated VTE, based on clinical trial data showing an overall improved safety and efficacy profile of LMWH compared to vitamin K antagonists. How...
4 CitationsSource
Abstract Venous thromboembolism (VTE) remains a substantial clinical and health-economic burden worldwide and effective anticoagulant treatment is necessary immediately after VTE is suspected to reduce short- and long-term VTE related morbidity and mortality. For decades, low molecular weight heparin (LMWH), fondaparinux and Vitamin K antagonists (VKAs) have been the standard of anticoagulant therapy for VTE patients but these treatment options had clinically relevant drawbacks and limitations. ...
6 CitationsSource